Effect of long‐term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis
- 4 June 2007
- journal article
- clinical trial
- Published by Wiley in Internal Medicine Journal
- Vol. 37 (7), 495-498
- https://doi.org/10.1111/j.1445-5994.2007.01404.x
Abstract
Recurrent Gram-negative bacterial infection is a significant cause of death in patients with bronchiectasis and severe chronic obstructive pulmonary disease (COPD). Nebulized colistin in cystic fibrosis has shown maintenance of pulmonary function and improved symptom scores. We prospectively followed 18 patients with chronic bronchial sepsis treated with nebulized colistin 30 mg daily. Mean decline in forced expiratory volume in 1 s was significantly slower following commencement of inhaled colistin (44 mL/year vs 104 mL/year, P = 0.035). Mean decline in forced vital capacity was also significantly slower following commencement of colistin (48 mL/year vs 110 mL/year, P = 0.033). Patient-reported quality of life improved following commencement of colistin (3.6 vs 6.2, P = 0.001). No patient had isolates resistant to colistin. No side-effects were reported by patients in the cohort. Use of inhaled colistin in the treatment of bronchiectasis and severe (COPD) in patients with recurrent Gram-negative infections is safe. Inhaled colistin may improve quality of life and slow decline in forced expiratory volume in 1 s and forced vital capacity.Keywords
This publication has 17 references indexed in Scilit:
- Improving rate of decline of FEV1 in young adults with cystic fibrosisThorax, 2006
- Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial InfectionsClinical Infectious Diseases, 2005
- A Pilot Study of the Safety and Efficacy of Tobramycin Solution for Inhalation in Patients With Severe Bronchiectasis*Chest, 2005
- Bronchiectasis, Exacerbation Indices, and Inflammation in Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agentsThorax, 2003
- Bronchial Inflammation and Colonization in Patients with Clinically Stable BronchiectasisAmerican Journal of Respiratory and Critical Care Medicine, 2001
- The Economic Burden of COPDChest, 2000
- Infective Exacerbations of Chronic BronchitisChest, 1998
- Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis.American Journal of Respiratory and Critical Care Medicine, 1997
- Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infectionJournal of Antimicrobial Chemotherapy, 1987